Clinicians frequently encounter incidental adrenal masses during routine cross-sectional abdominal imaging for unrelated indications. Navigating an appropriate adrenal incidentaloma workup requires a precise balance between diagnostic thoroughness and avoiding excessive testing. Although traditional guidelines recommended universal biochemical testing, modern diagnostic tools support a tailored, risk-stratified strategy.

Evolving Paradigms in the Adrenal Incidentaloma Workup

Historically, clinical practice guidelines instructed physicians to screen every discovered adrenal mass for endocrine hyperfunction. Practitioners routinely ordered comprehensive hormonal panels to rule out pheochromocytoma, autonomous cortisol excess, and primary aldosteronism. However, this indiscriminate screening strategy often generates false-positive laboratory results in healthy individuals. Consequently, patients frequently face unwarranted psychological distress, costly follow-up imaging, and unnecessary surgical operations.

In recent years, high-resolution cross-sectional imaging has transformed diagnostic accuracy. Modern unenhanced computed tomography scans reliably characterize microscopic tissue composition. Therefore, endocrine specialists now question the utility of indiscriminate hormonal testing for all patients. Instead of ordering blanket diagnostic panels, physicians can effectively stratify testing according to imaging characteristics and comorbid symptoms. Furthermore, registry data demonstrate that the vast majority of incidentalomas represent clinically silent, benign cortical adenomas. As a result, contemporary expert guidelines recommend selective, risk-stratified hormonal evaluations to optimize patient care and reduce diagnostic burden.

CT Attenuation and Lipid-Rich Benign Adenomas

Unenhanced computed tomography represents the gold standard for initially assessing incidental adrenal lesions. Specifically, radiologists determine attenuation values measured in Hounsfield units to estimate intracellular lipid content. Benign adrenocortical adenomas naturally contain abundant intracytoplasmic lipid droplets. Because lipids exhibit low radiological density, lipid-rich adenomas typically display attenuation values of ten Hounsfield units or lower on unenhanced computed tomography.

Consequently, identifying a homogeneous nodule below this ten-unit threshold provides reassuring diagnostic certainty. Extensive multicenter data demonstrate that such lesions carry virtually zero risk of primary adrenocortical carcinoma. Similarly, metastatic adrenal deposits almost universally exhibit unenhanced attenuation values far exceeding ten units. Therefore, detecting homogeneous low attenuation reliably confirms a benign histology without requiring repeated morphological imaging. However, physicians must ensure that the scan strictly represents unenhanced acquisition. Furthermore, establishing a definitive benign diagnosis on unenhanced imaging prevents needless surveillance scans and shields patients from ionizing radiation.

Rethinking Universal Screening for Pheochromocytoma

Traditional diagnostic algorithms mandated biochemical screening for pheochromocytoma in every patient with an adrenal mass. Clinicians ordered plasma free metanephrines or 24-hour urinary fractionated metanephrines to prevent unexpected perioperative hypertensive emergencies. However, recent scientific evidence questions this universal approach. Pheochromocytomas originate from chromaffin tissue and consistently lack substantial intracytoplasmic fat.

Large retrospective and prospective registries confirm that pheochromocytomas virtually always demonstrate attenuation values above ten Hounsfield units on unenhanced scans. In fact, most catecholamine-producing tumors display unenhanced attenuation values above thirty units. Consequently, the 2023 European Society of Endocrinology guidelines advise that clinicians may safely omit metanephrine testing in asymptomatic individuals with homogeneous masses exhibiting ten or fewer Hounsfield units. Nevertheless, physicians must maintain clinical suspicion in specific scenarios. If an adrenal lesion displays marked heterogeneity, central necrosis, or high unenhanced density, testing remains essential. In addition, when patients report episodic palpitations, diaphoresis, or severe hypertension, clinicians must exclude pheochromocytoma regardless of radiographic findings.

The Imperative to Detect Autonomous Cortisol Secretion

Unlike pheochromocytoma testing, evaluating autonomous cortisol secretion remains broadly recommended for nearly all adrenal incidentalomas. Cortical adenomas frequently display autonomous cortisol production independent of pituitary adrenocorticotropic hormone feedback. Endocrine specialists classify this subtle hormone activity as mild autonomous cortisol secretion. Affected individuals rarely exhibit obvious physical signs of Cushing syndrome, such as facial plethora, proximal muscle weakness, or violaceous abdominal striae.

However, mild autonomous cortisol secretion causes substantial long-term metabolic and cardiovascular harm. Observational studies demonstrate elevated rates of resistant hypertension, impaired glucose tolerance, dyslipidemia, and vertebral fragility fractures in these patients. Furthermore, large longitudinal cohorts associate persistent mild hypercortisolemia with increased cardiovascular and all-cause mortality. Therefore, establishing a timely diagnosis allows clinicians to initiate proactive medical management and mitigate systemic risks. Guidelines unanimously endorse the 1-milligram overnight dexamethasone suppression test as the premier screening investigation. Patients ingest one milligram of dexamethasone at bedtime, and clinicians measure serum cortisol the following morning. Consequently, routine cortisol testing remains an indispensable cornerstone of incidentaloma evaluation.

Targeted Biochemical Screening for Primary Aldosteronism

While physicians screen widely for autonomous cortisol, primary aldosteronism evaluation requires a selective approach. Aldosterone-producing adrenocortical adenomas autonomously release mineralocorticoids, causing volume expansion, urinary potassium wasting, and systemic hypertension. However, epidemiological investigations demonstrate that functioning aldosteronomas exceedingly rarely arise in normotensive individuals. Therefore, international guidelines advise clinicians to reserve aldosterone screening strictly for patients with documented hypertension or unexplained hypokalemia.

Clinicians evaluate suspected mineralocorticoid excess by determining the morning plasma aldosterone-to-renin ratio. An elevated ratio points toward autonomous aldosterone production and warrants confirmatory diagnostic testing. However, medical teams must interpret laboratory values carefully because multiple antihypertensive medications interfere with the renin-angiotensin-aldosterone axis. For instance, beta-adrenergic antagonists suppress renin and generate false-positive results, whereas diuretics stimulate renin and produce false-negative interpretations. When clinicians confirm unilateral primary aldosteronism, laparoscopic adrenalectomy provides an effective therapeutic option. Surgical resection frequently cures secondary hypertension and normalizes electrolyte balance. Thus, restricting screening to hypertensive patients maximizes diagnostic yield.

Implementing a Pragmatic Clinical Decision Pathway

Modern clinical practice demands an organized, evidence-based algorithm for managing incidental adrenal nodules. When initial cross-sectional imaging reveals an adrenal incidentaloma, the clinician must first scrutinize unenhanced computed tomography attenuation characteristics. If the mass demonstrates homogeneous texture with attenuation of ten Hounsfield units or lower, the clinician confirms a benign adenoma. Under these circumstances, physicians can omit metanephrine testing in asymptomatic individuals.

Next, the clinician arranges an overnight 1-milligram dexamethasone suppression test to rule out autonomous cortisol secretion. Simultaneously, the medical team evaluates resting blood pressure and serum potassium concentrations. If the patient exhibits hypertension or hypokalemia, the clinician measures the aldosterone-to-renin ratio. Conversely, clinicians omit aldosterone testing in normotensive patients. If the mass exhibits attenuation exceeding ten Hounsfield units or shows heterogeneous features, physicians must order metanephrines and refer the patient to a multidisciplinary endocrine team. Furthermore, indeterminate masses require dedicated endocrine surgeon and radiologist input. Ultimately, this risk-stratified strategy optimizes resource utilization, enhances patient safety, and reduces diagnostic confusion.

When can clinicians safely omit metanephrine testing in an adrenal incidentaloma?

Clinicians can safely omit metanephrine testing when an unenhanced computed tomography scan demonstrates a homogeneous adrenal mass with an attenuation value of ten Hounsfield units or lower in an asymptomatic patient. Extensive clinical investigations confirm that pheochromocytomas virtually always exhibit unenhanced attenuation values exceeding ten units because they lack abundant intracytoplasmic lipid. Therefore, patients with lipid-rich homogeneous lesions face an exceedingly low risk of pheochromocytoma, allowing physicians to bypass plasma metanephrine assays safely.

Why is cortisol screening recommended even if the patient appears asymptomatic?

Cortisol screening remains strongly recommended because mild autonomous cortisol secretion frequently occurs without overt symptoms like facial rounding or purple abdominal striae. Despite lacking obvious physical signs, patients experiencing subclinical hypercortisolemia face substantially higher risks of hypertension, type 2 diabetes, dyslipidemia, osteoporotic fractures, and cardiovascular morbidity. Consequently, performing a 1-milligram overnight dexamethasone suppression test enables early identification of insidious autonomous secretion, allowing clinicians to optimize metabolic therapy and prevent irreversible systemic complications.

Which patients with adrenal incidentalomas require primary aldosteronism screening?

Primary aldosteronism screening is strictly indicated for patients with adrenal incidentalomas who present with concomitant arterial hypertension, unexplained hypokalemia, or young-onset vascular disease. Because aldosterone-producing adenomas exceedingly rarely develop in normotensive populations, universal screening in individuals with normal blood pressure creates false-positive results without clinical utility. Clinicians evaluate at-risk hypertensive patients by calculating the morning plasma aldosterone-to-renin ratio after carefully adjusting any interfering antihypertensive medications that might distort endocrine results.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Pautler SE et al. Adrenal Incidentalomas: Do All Patients Require a Biochemical Workup? Eur Urol Focus. 2026 Oct 31. doi: undefined. PMID: 42966657.
2. Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42.
3. Sconfienza E, Pia A, Reimondo G, et al. Prevalence of Functioning Adrenal Incidentalomas: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023;108(7):1813-1823.